Thursday, September 29, 2022


Biotechnology News Magazine

CorEvitas and The Guthy-Jackson Charitable Foundation Announce the SPHERES Registry

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 30, 2021

CorEvitas and The Guthy-Jackson Charitable Foundation (GJCF) are excited to announce plans for launching the SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions in NMOSD) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD).

CorEvitas is the leading sponsor of registries in autoimmune and inflammatory diseases. In collaboration with GJCF, the SPHERES Registry is designed to better understand the benefit and safety of newly approved therapies for patients diagnosed with NMOSD.

“The SPHERES Registry will serve as a comprehensive real-world study to advance our knowledge of NMOSD in ways that directly help patients. Importantly, its focus will include safety and effectiveness of newly approved medications, evolving treatment patterns and access, and understanding patient experience over time.

The study will also enable research on cellular and molecular biomarkers through collection of biospecimens,” said Dr. Michael Yeaman, Professor of Medicine at the David Geffen School of Medicine at UCLA and Chair Medical Advisor to the Guthy-Jackson Charitable Foundation.

NMOSD is a rare neuroinflammatory autoimmune disease of the central nervous system, primarily targeting the optic nerves, spinal cord and brain.  It is currently estimated to afflict approximately 15,000 people in the U.S. and hundreds of thousands worldwide.  Historically, this disease has imposed significant physical and emotional disability and life-threatening outcomes.  Today, advances in diagnosis, biomarkers and newly FDA-approved treatment options offer patients with NMOSD promise to lessen or prevent disability and enhance quality of life.

“We are excited and truly honored to partner with GJCF on this collaborative research initiative, further demonstrating our deep commitment as a company to accelerating real-world evidence generation in neurologic diseases,” said Dr. Jeff Greenberg, Chief Medical Officer of CorEvitas.

Scientific experts in clinical research, epidemiology and biostatistics at CorEvitas will manage, operate and analyze data from the SPHERES Registry. Advisors from GJCF will serve on the scientific steering committee and facilitate state-of-the art research, building on the success and insights generated by the CIRCLES (Collaborative International Research in Clinical and Longitudinal Experience for NMOSD Studies) Registry.

The SPHERES registry represents the ongoing commitment of Genentech, a Member of the Roche Group, to support collaborative programs that benefit people living with NMOSD and their families. CorEvitas and GJCF look forward to additional industry partners joining this collaboration going forward. CorEvitas and GJCF are inviting sites and patients to join the registry to reach an enrollment goal of approximately 750 NMOSD patients.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine